Introduction and Aims: Deposition of C1q occurs in 0 to 45% of patients with IgAN. In order to identify whether mesangial C1q deposition in IgAN is a novel marker for the response to tonsillectomy plus steroid pulse therapy (TSP), we studied the association between mesangial C1q deposition in IgAN and the remission rate after TSP therapy for IgAN. Methods: We conducted a retrospective cohort study at a single Japanese center. We analyzed data on 110 patients diagnosed with IgA nephropathy who received TSP between January 2003 and December 2012. Positive C1q findings were defined as diffuse mesangial C1q deposition. The study outcome was the resolution of abnormal urinary findings and was defined as negative proteinuria and negative occult blood 1 year after steroid pulse therapy. Results: In all enrolled cases, 69 patients (62.7%) went into remission. Ten out of 24 (41.7%) C1q-positive patients experienced remission, and 59 out of 86 (68.6%) C1q-negative patients experienced remission. Multiple logistic regression model analysis showed that the absence of C1q deposition increased the odds ratio for remission (odds ratio 4.41; 95% confidence interval 1.33-15.75, p = 0.017). Conclusions: These results suggest that the absence of diffuse C1q deposition in the mesangial area of the glomerulus in patients with IgA nephropathy is a positive predictive sign for a response to TSP and is associated with the resolution of urinary abnormalities 1 year after TSP.

1.
Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 2013;368:2402-2414.
2.
Tomino Y, Sakai H; Special Study Group (IgA Nephropathy) on Progressive Glomerular Disease: Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol 2003;7:93-97.
3.
Bartosik LP, Lajoie G, Sugar L, et al: Predicting progression in IgA nephropathy. Am J Kidney Dis 2001;38:728-735.
4.
Berthoux F, Mohey H, Laurent B, et al: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011;22:752-761.
5.
Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177-3183.
6.
Wakai K, Kawamura T, Endoh M, et al: A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006;21:2800-2808.
7.
Donadio JV, Bergstralh EJ, Grande JP, et al: Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002;17:1197-1203.
8.
Cattran DC, Coppo R, Cook HT, et al: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534-545.
9.
Tanaka S, Ninomiya T, Katafuchi R, et al: Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol 2013;8:2082-2090.
10.
Katafuchi R, Ninomiya T, Nagata M, et al: Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol 2011;6:2806-2813.
11.
Barratt J, Feehally J: Treatment of IgA nephropathy. Kidney Int 2006;69:1934-1938.
12.
Donadio JV, Grande JP: The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 2004;24:225-243.
13.
Xie Y, Chen X, Nishi S, et al: Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004;65:1135-1144.
14.
Wang Y, Chen J, Chen Y, et al: A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 2011;26:1923-1931.
15.
Miura N, Imai H, Kikuchi S, et al: Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol 2009;13:460-466.
16.
Tabata T, Ohbuchi T, Kitamura T, et al: [Prognostic factors of IgA nephropathy after tonsillectomy]. Nihon Jibiinkoka Gakkai Kaiho 2012;115:836-841.
17.
Jennette JC: The immunohistology of IgA nephropathy. Am J Kidney Dis 1988;12:348-352.
18.
Woodroffe AJ, Gormly AA, McKenzie PE, Wootton AM, Thompson AJ, Seymour AE, et al: Immunologic studies in IgA nephropathy. Kidney Int 1980;18:366-374.
19.
Yoshimura M, Kida H, Abe T, Takeda S, Katagiri M, Hattori N: Significance of IgA deposits on the glomerular capillary walls in IgA nephropathy. Am J Kidney Dis 1987;9:404-409.
20.
Vangelista A, Frascà GM, Mondini S, Bonomini V: Idiopathic IgA mesangial nephropathy: immunohistological features. Contrib Nephrol 1984;40:167-173.
21.
Okada K, Funai M, Kawakami K, Kagami S, Yano I, Kuroda Y: IgA nephropathy in Japanese children and adults: a comparative study of clinicopathological features. Am J Nephrol 1990;10:191-197.
22.
Smith SM: IgA nephropathy: characterization of the light chains. Clin Nephrol 1990;34:93-94.
23.
Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E: Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 1987;31:820-829.
24.
McCoy RC, Abramowsky CR, Tisher CC: IgA nephropathy. Am J Pathol 1974;76:123-144.
25.
Lee HJ, Choi SY, Jeong KH, et al: Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol 2013;80:98-104.
26.
Matsuo S, Imai E, Horio M, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
27.
Hotta O, Miyazaki M, Furuta T, et al: Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001;38:736-743.
28.
Bogers WM, Stad RK, van Es LA, et al: Immunoglobulin A: interaction with complement, phagocytic cells and endothelial cells. Complement Inflamm 1991;8:347-358.
29.
Liu LL, Wang LN, Jiang Y, Yao L, Dong LP, Li ZL, et al: Tonsillectomy for IgA Nephropathy: a meta-analysis. Am J Kidney Dis 2015;65:80-87.
30.
Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, et al: A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014;29:1546-1553.
31.
Hisano S, Fukuma Y, Segawa Y, et al: Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol 2008;3:1637-1643.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.